Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  •  
     

    Dana H. Gabuzda, MD

    Professor of Neurology, Harvard Medical School
     
     

    About Gabuzda Lab

    HIV molecular biology and pathogenesis

    The Gabuzda lab uses genetic, biochemical, metabolomic, systems biology, and computational approaches to study HIV infection and comorbidities including cancer. Research interests include understanding viral, host, and environmental factors that determine clinical outcomes, therapeutic responses, and accelerated aging. 

    Current projects include studies on: 1) virus-host interactions during HIV replication and pathogenesis that impact immune control, inflammation, metabolic disorders, and comorbidities; 2) role of exosomes in cell-cell communication, immune regulation, stress responses, and disease pathophysiology; 3) mechanisms involved in HIV-associated neurological disorders and accelerated aging; 4) cancer risk and etiologies in aging populations with HIV. 

    The lab is proficient at bioinformatic, computational, and systems biology approaches including generation, analysis, interpretation, and visualization of large data sets, big data handling, and using bioinformatic software and R programs for data integration, network prediction, pathway analysis, and modeling. The lab also uses machine learning and other computational approaches to model longitudinal trajectories and identify new predictors of clinical outcomes. The long-term goal is gaining multidisciplinary knowledge that leads to progress in personalized medicine for HIV-infected and aging populations.